Background: Previous studies using transesophageal echocardiography (TEE) report an association of valvular heart disease (VHD) with cerebral infarcts and central neuropsychiatric systemic lupus erythematosus (NPSLE). However, TEE cannot be routinely used. Aim: To determine if VHD detected by transthoracic echocardiography (TTE) is associated with focal brain injury on magnetic resonance imaging (MRI) and secondarily with central NPSLE. Methods: Sixty-nine patients with systemic lupus erythematosus underwent general clinical, neuropsychiatric and laboratory evaluations followed by MRI of the brain and TTE. Results: Forty-one patients (59%) had NPSLE (stroke, transient ischemic attack, cognitive dysfunction, acute confusional state, seizures or psychosis); 46 (67%) had focal brain injury on MRI (cerebral infarcts, white matter lesions or small punctate lesions); 38 (55%) had VHD (vegetations, thickening or regurgitation). VHD was more common in patients with than in those without focal brain injury and NPSLE (all p < 0.05); focal brain lesions were more common in patients with than in those without NPSLE (all p < 0.04); and VHD was an independent predictor of focal brain lesions and NPSLE (both p < 0.04). Conclusion: In patients with systemic lupus erythematosus, VHD detected by TTE is associated with focal brain injury and NPSLE.

Keywords:
Valvular heart disease, Transthoracic echocardiography, Magnetic resonance imaging, Neuropsychiatric systemic lupus erythematosus, Antiphospholipid antibodies
1.
Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr: Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005;95:1441–1447.
2.
Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr: Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol 2006;12:3–10.
3.
Roldan CA, Shively BK, Crawford MH: An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996;335:1424–1430.
4.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.
5.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725–1726.
6.
Ghaussy NO, Sibbitt WL Jr, Qualls CR, Bankhurst AD: Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003;30:1215–1221.
7.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–640.
8.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–369.
9.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.
10.
Nelson A, Fogel BS, Faust D: Bedside cognitive screening instruments: a critical assessment. J Nerv Ment Dis 1986;174:73–83.
11.
Lezak MD: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995, pp 1–173.
12.
Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, Bankhurst AD, Brooks WM: The incidence and prevalence of neuropsychiatric syndromes in pediatric-onset systemic lupus erythematosus. J Rheumatol 2002;29:1536–1542.
13.
Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM: Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 2003;30:1983–1989.
14.
Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P: Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004;46:15–21.
15.
Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA: Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777–802.
16.
Stimmler MM, Coletti PM, Quismorio FP Jr: Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993;22:335–349.
17.
Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E: Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998;41:41–47.
18.
Morelli S, Bernardo ML, Viganego F, Sgreccia A, De Marzio P, Conti F, Priori R, Valesini G: Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus 2003;12:805–812.
19.
Munoz-Rodriguez FJ, Reverter Calatayud JC, Font Franco J, Espinosa Garriga G, Tassies Penella D, Ingelmo Morin M: Valvular heart disease in patients with anti-phospholipid syndrome. Rev Clin Esp 2002;202:529–533.
20.
Futrell N, Millikan C: Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989;20:583–591.
21.
Devinsky O, Petito CK, Alonso DR: Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:380–384.
22.
Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P: Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004;31:1344–1348.
23.
Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, Rovensky J, Chapman J, Shoenfeld Y: Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005;64:1490–1493.
24.
Ellis SG, Verity MA: Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 1979;8:212–221.
25.
Ellison D, Gatter K, Heryet A, Esiri M: Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol 1993;46:37–40.
26.
Fox IS, Spence AM, Wheelis RF, Healey LA: Cerebral embolism in Libman-Sacks endocarditis. Neurology 1980;30:487–491.
27.
Gorelick PB, Rusinowitz MS, Tiku M, McDonald LW, Robbins L: Embolic stroke complicating systemic lupus erythematosus. Arch Neurol 1985;42:813–815.
28.
Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM: Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998;29:2254–2260.
29.
Barbut D, Borer JS, Wallerson D, Ameisen O, Lockshin M: Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. Cardiology 1991;79:99–109.
30.
Kumral E, Evyapan D, Keser G, Kabasakal Y, Oksel F, Aksu K, Balkir K: Detection of microemboli signals in patients with neuropsychiatric lupus erythematosus. Eur Neurol 2002;47:131–135.
31.
Rademacher J, Sohngen D, Specker C, Janda I, Sitzer M: Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus? Acta Neurol Scand 1999;99:356–361.
32.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003:349:2399–2406.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.